Cel Peri-implant disease (Mucositis and peri-implantitis) is a major and growing clinical problem in odontology, affecting 20-40mill. patients in Europe, and the double worldwide. Labrida has developed, clinically documented and CE marked a novel,patented (pending) maintenance device for non-surgical management of peri-implant disease. It is a revision brush(“BioClean”), with bioresorbable bristles made of mono-filament chitosan fibres (Patented by Medovent, DE). It offers safer,more effective, less painful and faster treatment of peri-implant disease, where currently the clinical community is in searchfor adequate solutions. The instrument addresses a market in the range of Euro 1-2 billion annual turnover.The device is in small scale production and sold commercially in Scandinavia (TRL 7), with most promising market response.To meet the market opportunity, we will develop up-scaled production processes of advanced chitosan fibres, which iscritical to increase overall production requirements. In addition, we have started development with clinical pilot testing of thenext generation product, comprising chitosan bristles combined with antibiotics, with interesting clinical results. This mayopen a broader application field for deployment of these combinations of materials technologies, both within odontology andwider in medicine.The overall planned project (Phase 2) comprises both industrial development of scaled up production technologies for thechitosan fibres of the currently marketed product , as well as development of the next generation product, combiningadvanced chitosan technologies with bioactive material, e.g. in nanospheres. In phase 1, we intend to refine thedevelopment plan of these product(s) for phase 2, including assessing more in detail the business case, and additionalapplication areas, of the 2nd generation product. Dziedzina nauki medical and health sciencesclinical medicinegeneral medicine Program(-y) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Temat(-y) NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2014 System finansowania SME-1 - SME instrument phase 1 Koordynator LABRIDA AS Wkład UE netto € 50 000,00 Adres Theodor lovstads vei 32 0286 Oslo Norwegia Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Norge Oslo og Viken Oslo Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00